Apontis Pharma’s €101 Million Initial Public Offering

McDermott Will & Emery acted as Transaction Counsel for the issuer, its main shareholder Paragon Partners as well as the Joint Bookrunners Hauck & Aufhäuser and M.M.Warburg with regard to the IPO.

APONTIS PHARMA AG executed its IPO on the Frankfurt stock exchange. The placement price for its initial public offering (“IPO”) was set at EUR 19,00 per share. In total, 5,290,000 ordinary bearer shares with no par value were placed with investors in the IPO, which also included a U.S. tranche under Rule 144A of the U.S. Securities Act. The placement comprises 2,000,000 new shares from a capital increase against cash contributions, 1,600,000 secondary shares in a base deal and 1,000,000 secondary shares from the exercise of an upsize option by the major shareholder Paragon Partners as well as 690,000 secondary shares provided by Paragon Partners in connection with an over-allotment option, corresponding to a total placement volume of EUR 101 million. The existing shareholders, Paragon Partners and APONTIS PHARMA’s Management, will continue to hold 31% and 7% of the Company’s shares following the placement, respectively.

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in the German market. APONTIS PHARMA intends to use the net proceeds from the issuance of the new shares to primarily pursue selected investments in the development of new Single Pills, the acceleration of the development and licensing of its existing short-term product pipeline and the expansion of its marketing and sales activities to capture further market share as well as product acquisitions.

The McDermott team advising APONTIS PHARMA, Paragon Partners and the banks was led by Frankfurt partners Simon Weiß (Picture) and Joseph W. Marx and comprised Gregory M. Weigand, counsels Edwin C. Laurenson, Deniz Tschammler, Monika Richter, associates Marion von Grönheim, Isabelle Suzanne Müller, Christoph Schäfer, and staff attorney Ardalan Zargari. The corporate workstream was led by Duesseldorf partner Philipp Grenzebach and his team included Thomas Gennert and associate Tom Schäfer.

Involved fees earner: Thomas Gennert – McDermott Will & Emery; Philipp Grenzebach – McDermott Will & Emery; Edwin Laurenson – McDermott Will & Emery; Joseph Marx – McDermott Will & Emery; Isabelle Müller – McDermott Will & Emery; Monika Emilia Richter – McDermott Will & Emery; Deniz Tschammler – McDermott Will & Emery; Gregory Weigand – McDermott Will & Emery; Simon Weiß – McDermott Will & Emery; Ardalan Zargari – McDermott Will & Emery; Marion von Grönheim – Shearman & Sterling;

Law Firms: McDermott Will & Emery; Shearman & Sterling;

Clients: Apontis Pharma; Hauck & Aufhäuser Privatbankiers KGaA; M.M.Warburg & CO; Paragon Partners;

Author: Federica Tiefenthaler